<DOC>
	<DOCNO>NCT02513667</DOCNO>
	<brief_summary>The purpose study see Ceritinib target ALK non-small cell lung cancer slow cancer growth prevent spreading .</brief_summary>
	<brief_title>Ceritinib Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma</brief_title>
	<detailed_description>This , open-label , two-cohort protocol design evaluate activity target therapy SABR ALK positive lung adenocarcinoma . Cohort A evaluate combination ALK-inhibitor naïve patient . Cohort B evaluate combination patient receive treatment one prior ALK inhibitor . Ceritinib administer patient disease progression RECIST 1.1 , unacceptable toxicity , withdrawal consent , discontinuation trial reason include death . The primary focus protocol identify response ALK+ lung cancer patient . Patients Ventana assay Vysis FISH probe positive tumor treat . Evidence ALK gene rearrangement also consider eligible trial . Primary Objective : Cohort A : Superiority ceritinib + SABR median PFS compare historical control 10 month ( expect 20 month ) Endpoint : Cohort A Median PFS define time initiation ceritinib disease progression RECIST 1.1 , unacceptable toxicity , withdrawal consent , discontinuation trial reason include death . Primary : Cohort B : Superiority ceritinib + SABR median PFS compare historical control 7 month . Endpoint : Cohort B : Median PFS define time initiation ceritinib disease progression RECIST 1.1 , unacceptable toxicity , withdrawal consent , discontinuation trial reason include death . Secondary : - Report Overall survival Overall survival - Report Time 2nd SABR Time start systemic therapy first day second course SABR - Report Time 3rd SABR Time start therapy first day third course SABR - Report proportion patient CR/PR/stable disease 6 and12 month Number patient CR/PR/stable disease 6 12 month initiation Safety : -Demonstrate safety ceritinib follow SABR Describe toxicity adverse event ( CTCAE v.4 ) compare historical control .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Ceritinib</mesh_term>
	<criteria>1 . Histologically cytologically confirm diagnosis lung adenocarcinoma demonstrate ALK rearrangement detect approved FISH test ( Abbott Molecular Inc ) , use Vysis breakapart probe ( define 15 % positive tumor cell ) ; Ventana IHC test . Evidence rearrangement gene sequence test FoundationOne Caris also see evidence ALK abnormality meeting eligibility requirement . 2 . Patients prior ALKinhibitor therapy place cohort A , treat one prior line ALKinhibitor ( time ) enter cohort B . 3 . Patients curative therapeutic option , radiation surgery . 4. WHO performance status 02 . 5 . Age ≥18 year . 6 . Patients must recover toxicity relate prior anticancer therapy ≤ Grade 2 ( CTCAE v 4.03 ) , provide concomitant medication give prior initiation treatment ceritinib . Exception criterion : patient grade alopecia allow enter treatment . 7 . Adequate organ function : follow laboratory criterion meet : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Hemoglobin ( Hgb ) ≥ 8 g/dL Platelets ≥ 75 x 109/L Serum creatinine &lt; 1.5 mg/dL /or calculate creatinine clearance ( use CockcroftGault formula ) ≥30 mL/min Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) , except patient Gilbert 's syndrome may include total bilirubin ≤ 3.0 x ULN direct bilirubin ≤ 1.5 x ULN Aspartate transaminase ( AST ) &lt; 2.0 x ULN , except patient liver metastasis , include AST &lt; 3 x ULN ; alanine transaminase ( ALT ) &lt; 2.0 x ULN , except patient liver metastasis , include ALT &lt; 3 x ULN Alkaline phosphatase ( ALP ) ≤5.0 x ULN Fasting plasma glucose ≤175 mg/dL ( ≤9.8 mmol/L ) Serum amylase ≤ 2 x ULN Serum lipase ≤ ULN 8 . Patient must follow laboratory value follow laboratory value correct supplement within normal limit first dose ceritinib : Potassium Magnesium Phosphorus Total calcium ( correct serum albumin ) 9 . Written inform consent protocol must obtain prior screen procedure . 10 . Willingness ability comply schedule visit , treatment plan , laboratory test procedure . 1 . Patients know hypersensitivity excipients ceritinib ( microcrystalline cellulose , mannitol , crospovidone , colloidal silicon dioxide magnesium stearate ) . 2 . History carcinomatous meningitis . 3 . Prior therapy ceritinib . 4 . Presence history malignant disease lung adenocarcinoma diagnose and/or require therapy within past year undergo active anticancer treatment . Exceptions exclusion include follow : completely resect basal cell squamous cell skin cancer , completely resect carcinoma situ type . 5 . Patient history interstitial lung disease interstitial pneumonitis , include clinically significant radiation pneumonitis ( i.e. , affecting activity daily live require therapeutic intervention ) . 6 . Patient receive thoracic radiotherapy lung field ≤4 week prior start study treatment patient recover radiotherapyrelated toxicity . For anatomic site ( include radiotherapy thoracic vertebra rib ) radiotherapy ≤2 week prior start study treatment recover radiotherapyrelated toxicity . Palliative radiotherapy bone lesion ≤2 week prior start study treatment allow . 7 . Patient clinically significant , uncontrolled heart disease and/or recent cardiac event ( within 6 month ) , : unstable angina within 6 month prior screen ; myocardial infarction within 6 month prior screen ; history document congestive heart failure ( New York Heart Association functional classification IIIIV ) ; uncontrolled hypertension define Systolic Blood Pressure ( SBP ) ≥ 160 mm Hg and/or Diastolic Blood Pressure ( DBP ) ≥ 100 mm Hg , without antihypertensive medication initiation adjustment antihypertensive medication ( ) allow prior screening ; ventricular arrhythmia ; supraventricular nodal arrhythmia control medication ; cardiac arrhythmia control medication ; Corrected QT ( QTcF ) &gt; 470 m use Fridericia 's correction screen ECG 8 . Impaired GI function GI disease may alter absorption ceritinib inability swallow five ceritinib capsule daily . Although , patient unable swallow capsule allow participate study , follow specific instruction make slurry medication . 9 . Patient impairment GI function GI disease may significantly alter absorption ceritinib ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome ) . 10 . Receiving medication meet one follow criterion discontinue least 1 week prior start treatment ceritinib duration participation ( see Appendix 1 Tables ) : Medication know risk prolong QT interval induce Torsades de Pointes ( please refer http : //www.azcert.org/medicalpros/druglists/druglists.cfm ) Strong inhibitor strong inducer CYP3A4/5 ( please refer http : //medicine.iupui.edu/flockhart/table.htm http : //www.druginteractioninfo.org ) Medications low therapeutic index primarily metabolize CYP3A4/5 , CYP2C8 and/or CYP2C9 ( please refer http : //medicine.iupui.edu/flockhart/table.htm http : //www.druginteractioninfo.org ) Therapeutic dose warfarin sodium ( Coumadin ) coumadinderived anticoagulant . Anticoagulants derive warfarin allow ( eg , dabigatran , rivaroxaban , apixaban ) . Unstable increase dos corticosteroid ; If patient corticosteroids endocrine deficiency tumorassociated symptom ( nonCNS ) , dose must stabilize ( decrease ) least 5 day first dose study treatment . Enzymeinducing anticonvulsive agent Herbal supplement 11 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test . 12 . Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose agree continue 3 month last dose study treatment . Highly effective contraception method include : Total abstinence ( line prefer usual lifestyle subject . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . Female sterilization ( surgical bilateral oophorectomy without hysterectomy ) tubal ligation least six week take study treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment . Male sterilization ( least 6 month prior screen ) appropriate postvasectomy documentation absence sperm ejaculate . For female subject study vasectomized male partner sole partner subject . Combination two follow ( a+b a+c b+c ) : 1 . Use oral , injected implant hormonal method contraception form hormonal contraception comparable efficacy ( failure rate &lt; 1 % ) , example hormone vaginal ring transdermal hormone contraception . 2 . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) . 3 . Barrier method contraception : Condom Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/vaginal suppository . In case use oral contraception , woman stable pill minimum 3 month take study treatment . Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g. , age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least six week prior screen . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential . 13 . Sexually active male unless agree use condom intercourse take drug agree continue 3 month last dose study treatment . Male patient 3 month father child period . A condom require use also vasectomize men order prevent delivery drug via seminal fluid . 14 . Patient history pancreatitis history increase amylase lipase due pancreatic disease . 15 . Patient severe , acute , chronic medical condition include uncontrolled diabetes mellitus psychiatric condition laboratory abnormality , opinion investigator , may increase risk associate study participation may interfere interpretation study result . 16 . Patient major surgery ( e.g. , intrathoracic , intraabdominal intrapelvic ) within 4 week prior start study treatment recover side effect procedure . Videoassisted thoracic surgery ( VATS ) mediastinoscopy count major surgery patient receive study treatment ≥1 week procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>